Financial Results for the First Half of
Fiscal Year Ending March 31, 2021 (FY2020)

from the beginning

Alliance Business
Develop a Growth Driver by Infusing Core Technologies with a New Business Model

• Safe Harbor for Forward-Looking StatementsandUse of Document

• “Alliance” Business within Terumo

• Alliance Business Trajectory

• Entering Growth Phase

• Unique Business Model

• Captured Emerging Needs for Change in Drug Trend

• Next Moves for Sustainable Growth

• Seamlessly Expanding Development Pipeline

• Expand Production Capability thru Constant Investments

• KSF to Secure Sustainable Growth Trajectory

• ExtendOurMarket Reach with “Alliance” Model

Financial Results for the First Half of Fiscal Year Ending March 31, 2021 (FY2020)

• Safe Harbor for Forward-Looking StatementsandUse of Document

• Revenue and Profits Were Ahead of Schedule Toward FY20 Guidance

• Adjusted Operating Profit Variance Analysis

• Revenue by Region

• Revenue by Business Segment

• Cardiac and Vascular: Elective Procedures Backlogs Were Being Cleared

• General : Covered the Impact of Decreased Demand by Solid HospitalSales of Alliance and Infection Control Products

• Blood and CellTechnologies: Continuous Increase in Both Revenue and Profit

• Revision of FY20 Guidance

• Key Assumptions of 2H FY20 Projection

• Major Topics in FY20 Q2

• FY20 New Product Pipeline

Reference

• 1H FY20 Revenue and Growth by Region

• Operating Expenses

• Quarterly Results

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and R&D Expenses

• Cash Flows

• Foreign Exchange Sensitivity

• The Status of Convertible Bonds